Clinical Trial Update: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for intravitreal aflibercept in treating submacular vascularized pigment epithelial detachments; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submacular Vascularized Pigment Epithelial Detachments

Drugs mentioned

• Eylea (aflibercept) (aflibercept)

Snippet

Sponsor: Southern California Desert Retina Consultants, MC | Conditions: Submacular Vascularized Pigment Epithelial Detachments | Phase 4 | Status: COMPLETED